AGC Biologics partners with Pyramid Pharma Services to add US drug-product manufacturing
- AGC Biologics will handle drug substance process development and manufacturing.
- Pyramid Pharma Services will provide sterile fill-finish for vials (liquid and lyophilized), pre-filled syringes, and cartridges, plus device assembly, labeling and secondary packaging in the US.
- Integrated project management between the firms is expected to reduce process transfer complexity and shorten development timelines.
- Combined with AGC Biologics’ existing European drug-product capabilities, the partnership aims to improve global supply-chain flexibility and stability for clinical programs.
Partnership scope
AGC Biologics has entered a strategic partnership with Pyramid Pharma Services to expand its U.S.-based development and manufacturing platform from drug substance to drug product. Under the agreement, AGC Biologics will be responsible for drug substance process development and manufacturing while Pyramid will provide sterile fill-finish and drug product capabilities.
Services and capabilities
The combined offering includes sterile fill-finish services for vials (liquid and lyophilized), pre-filled syringes, and cartridges, as well as device assembly, labeling, and secondary packaging services within the United States.
Operational impact
Integrated project management between the companies is expected to reduce process transfer complexity and shorten development timelines, enhancing development efficiency and supply stability. The partnership is intended to support an integrated supply capability for clinical programs and, together with AGC Biologics’ existing drug product-related capabilities in Europe, to strengthen global supply chain flexibility and help enable timely delivery of medicines to patients.
Source: AGC
